Skip Navigation


Annals of Oncology Advance Access originally published online on February 13, 2008
Annals of Oncology 2008 19(3):595-597; doi:10.1093/annonc/mdn021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/3/595-a    most recent
mdn021v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cottu, P. H.
Right arrow Articles by Vincent-Salomon, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cottu, P. H.
Right arrow Articles by Vincent-Salomon, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

letters to the editor

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

The first 10% of the full text of this article appears below.

HER2/neu oncogene overexpression has become a paramount prognostic and predictive marker in invasive breast carcinoma [1]. Its expression is usually highly homogeneous in malignant tissue [2]. Some cases of intratumoral heterogeneity have, however, been reported [3] (Figure 1). The impact of this heterogeneity on the natural history of breast cancer and its consequences on clinical management are unknown. We report here three clinical cases illustrating . . . [Full Text of this Article]

P. H. Cottu1,*, J. Asselah1, M. Lae2, J.-Y. Pierga1, V. Diéras1, L. Mignot1, B. Sigal-Zafrani2 and A. Vincent-Salomon2

1 Department of Medical Oncology
2 Department of Pathology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France

* (E-mail: paul.cottu@curie.net)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
Ann. Onc., November 4, 2009; (2009) mdp488v1.
[Abstract] [Full Text] [PDF]